Inhibitor Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $8.95 Mil.
During the past 12 months, Inhibitor Therapeutics's average Total Assets Growth Rate was 354.20% per year.
During the past 3 years, the average Total Assets Growth Rate was 24.10% per year.
During the past 5 years, the average Total Assets Growth Rate was -14.60% per year.
During the past 10 years, the average Total Assets Growth Rate was -5.60% per year.
During the past 13 years, Inhibitor Therapeutics's highest 3-Year average Total Assets Growth Rate was 256.50%. The lowest was -88.20%. And the median was -1.10%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Inhibitor Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibitor Therapeutics (OTCPK:INTI) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Inhibitor Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Inhibitor Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Inhibitor Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Inhibitor Therapeutics (Inhibitor Therapeutics) Business Description
Inhibitor Therapeutics Inc is a pharmaceutical development company focused on developing and commercializing therapies for patients with cancer and non-cancerous proliferation disorders. The company's main focus is to advance its lead product, SUBA-Itraconazole a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for prostate and lung cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INTI has been successfully added to your 